Ladies and gentlemen, thank you for standing by, and welcome to the NVE Conference Call on Second Quarter Results. At this time, all participants are in a listen only mode. After the speaker presentation, there will be a question and I would now like to hand the conference over to your speaker today, Ms. Daniel Baker, President and CEO. Thank you.
Please go ahead.
Good afternoon, and welcome to our conference call for the quarter end September 30, 2020. As always, I'm joined by Kurt Reinders, our Chief Financial Officer. This call is being webcast live and being recorded a replay will be available through our website nd.com. After my opening comments, Kurt will present a financial review of the quarter and I'll cover the business and then we'll open the call for questions. We issued our press release and filed our quarterly report on Form 10 Q in the past hour following the close of market Links to documents are available through the SEC's website, our website, and our Twitter timeline.
Comments we may make that relate to future plans, events, financial results or performance are forward looking statements that are subject to certain risks and uncertainties including among others such factors as risks and uncertainties related to future sales and revenue, uncertainties related to future stock repurchases and dividend payments, risks related to the COVID 19 pandemic as well as the risk factors listed from time to time in our filings with the SEC including our annual report on Form 10 K for the fiscal year ended March 31, 2020, as updated in our just filed quarterly report on Form 10 Q. Actual results could differ materially from the information provided, and we undertake no obligation to update forward looking statements we may make. As expected, the COVID-nineteen pandemic had a significant impact on our business the past quarter. Revenue in the most recent quarter decreased 33% and net income decreased 42% compared to the prior year, but we are pleased to report a solid profit for the quarter despite the significant impact of COVID-nineteen. The long term future continues to be bright and we continue to preserve our workforce invest in product development and pay generous dividends.
Now, Kurt will cover details of our financial results. Kurt?
Thanks, Dan. As Dan said, total revenue for the quarter ended September 30, 2020 decreased 33% compared to last year, due to a 33% decrease in product sales and a 29% decrease in contract R and D revenue. We believe the COVID 19 pandemic had a significant negative impact on our results of operations in the past quarter especially in medical device markets as many elective procedures were postponed. We continue to expect the pandemic to continue to have a significant negative impact Important customers, especially medical device customers have delayed and decreased orders due to the impact of COVID-nineteen. However, based on input from these customers, we currently expect product sales to begin to recover in early 2021.
Expenses decreased 9% for the 2nd quarter and a 3% decrease in SG And A. The decrease in R And D expense was due to the completion of some new product developments. Dan will discuss product development in a few minutes. Interest income for the 2nd quarter decreased 12% due to a decrease in our marketable securities and money market funds and a decrease in Net income for the quarter was $2,220,000 or $0.46 per diluted share compared to $3,820,000 or $0.79 last year. Despite the unprecedented challenges, our gross margin was 79%, operating margin was 52% and net margin was 51 percent.
And today, we announced that our board declared another quarterly dividend of $1 per share, payable November 30, to shareholders of record as of November 2nd. We believe our stock is a good investment and we took advantage of a weak stock market in the quarter to repurchase more than $91,000 We returned a total of more than $4,900,000 to shareholders in the quarter. For the 1st 6 months of the fiscal year, total revenue decreased 30% due to a 31% decrease product sales and a 14% decrease in contract R And D. Net income for the first half decreased 38 percent to $4,630,000 or $0.96 per share compared to $7,430,000 or $1.53 per share last fiscal year. Our balance sheet remains strong as cash plus marketable securities was $67,900,000 as of September 30.
Now I'll turn the call back to Dan to cover
pandemic, we continue to innovate and we look forward to helping automate infrastructure and improve medical devices when the world returns to normal. We had several new sensor and coupler product launches in the quarter. The sensor products were a new line of ultra precise motion sensor motion sensors and the new smart sensor model. The new AET series motion sensors were developed in response to customer requests and can be used for rotary or linear motion. There are 5 AET series models with various resolutions typical resolution is as little as 0.5 microns, less than a 10000th of an inch for linear motion sensing and point 02 degrees for rotation sensing.
These sensors are targeted at manufacturing factory automation. Demstration videos are available on our website in our YouTube channel, which show the remarkable resolution. The new smart sensor is a tunneling magnetoresistance magnetometer with a network interface called the inter integrated its circuit or I squared C. I squared C requires just two pins. So it maximizes the functionality of our Ultra miniature sensors, which are less than a 10th of an inch square, and have a total of 6 pins.
These sensors are targeted at motor control for factory automation and longer term for automotive applications. A new video demonstrates motor control using 5 different NV parts, which were introduced in the past year, including the new smart sensor. The new smart sensor is used as a current sensor. The other 4 new products used for motor control are a smart angle sensor isolators and DC to DC converters. Turning to couplers, until recently, our Coupler products isolated digital data, meaning they transmit data without a direct electrical connection.
These new power conversion products are called DC to DC converters and transmit power rather than data. This is useful in to combine the new DC to DC converters with network interfaces to simultaneously transfer both data and power in less space and with fewer chips. The 2 new parts have best in class data speed to quickly transfer the rich data streams and the internet of things. There's a link to the new Coupler product announcement on the press releases page of the News section of our website. There's also a demonstration in the video section of our website and on our YouTube channel.
The demonstration implements a simple but robust two computer network using the new products 1st trade show since the pandemic, Sensors Expo in San Jose in November, but that was cancelled. Sensors Expo is billed as North America's law just event dedicated to sensors, connectivity, and the internet of things. We're hopeful trade shows will resume year, and we've already signed up for the Next Sensors Expo in June 2021. Turning to governance Our annual shareholders meeting was in August via webcast and telephone. We're sorry we couldn't meet with many of you in person as we have for years, but of course, our first obligation is to the safety of our shareholders and other attendees.
You can visit our YouTube channel for a playlist product demonstrations that would have been at an in person meeting. For good corporate practice, our entire Board of Directors stands for election every year, and each of our directors was overwhelmingly reelected. Our executive officer compensation supports improving long term shareholder value not being excessive and shareholders overwhelmingly voted to approve compensation. And finally, the selection of our auditors was ratified. We filed an Eight K with details of the shareholder votes after the meeting.
Now I'd like to open the call for questions. Jimmy?
Thank you. Our first question comes from Jeff Bernstein with Cowen. Your line is now open.
Congratulations on the quarter, some really nice cash flow from operations in a tough period.
Thanks, Jeff. Yes, we were, chose the underlying strength of our technology and we were able to reduce some costs in the face of the pandemic.
So I had a couple of questions. I wanted to talk a little bit about hearing aids, a strong IPO by Ergo recently. And, despite the fact that the FDA never hit their deadline of August 8 team for rulemaking on over the counter, a year ago is pitching that, hey, at $4500 for a full fledged hearing aids, costs is way too high. The distribution channel doesn't make sense and poised to be disrupted. And a lot of potential growth out there.
So with that in mind, can you talk a little bit about what your outlook is there? Could you help us at all? Are you in year ago or bose or some of the new entrants that are out there?
Yes, that's a good question. And, as far as the timing, Of course, the FDA has been pretty busy with other things. But some of the industry now expect the regulations to be adopted by the end of the year. So then a final rule is due within 6 months, as you know, of the close of the comment period, So that would put us into late 2021. But in the meantime, we have been working on what's sometimes called hearables and as well as potential over the counter hearing aid suppliers.
And as you noted, there's a company that that has filed a prospectus looking at over the counter hearing aids to reduce the inconvenience of dispensing. And those are rechargeable. So there's a lot of activity in rechargeable hearing aid and hearing devices. So for us, that's a technical difference. Rechargeable batteries are higher voltage than disposable battery that are common in traditional hearing aids.
But we have products for that that we've developed and qualified that are ideal for those parts. We've been working with a number of companies probably wouldn't be appropriate for us to say, say specifically whom, but that's an area of focus for us. Potential. And we certainly want to be ready when the FDA finally does act. And also in parallel, the hearables market, which are not technically hearing aids.
If they're not hearing aids, they're not subject to the FDA regulation. And those are going on now continuing to be developed. And we're working with companies there. I think we've mentioned before, we have a design win in that space. That's the non hearing aid hearables market.
Great. Thanks for that. And then I was curious you guys, and you and I, traded an email about this during the quarter, the DARPA development of ultra low power sensors that can kind of stay out in the field for long, long periods of time, which sounds like it's something that's up your alley. But in particular, I was curious about whether you guys can actually make transducers with your technology.
Right. So, we can, we can interface to transducers. So many transducers can produce motion or magnetic fields. And so our sensors, which are very low power, can replace some of the other types of transducers that are converting other types of sensor inputs such as piezoelectric, which tends to use more power optical So our devices, as you know, are extremely low power. And that is one of the things that we're looking at is while we don't typically make the other types sensor elements for some of the things that DARPA was specifically looking at, we can provide an end node to that cloud or internet things, that's lower power and high reliability and not susceptible to reverse engineering or to hacking.
So those are all things that are of interest in that market and other markets.
Got you. Okay. And I'll get back in queue in a minute, but just real quick, Abbott, was pretty positive this morning on rebounding demand for some of their cardio related products that I think involve your parts. It sounded like you were saying that next quarter, you would still be down year to year on revenues. I'm just wondering whether you are thinking that you could be flat to up sequentially.
Kurt, do you want to address that?
Yeah. It's, there's a lot of uncertainty out there, and we are planning for a significant year over year revenue decrease this quarter. The 4th quarter we're expecting product sales to start to recover and we expect to see a significant sequential revenue growth in the 4th fiscal
Abbott reported this morning a 6% decrease in Rhythm Management devices. So that continues to be a challenging market. Now that's not as bad as the prior quarter where they reported a 27% decrease what would have been the 2nd calendar quarter. And, neuromodulation has been even more challenging. But, but it does it is showing signs of recovery, which is encouraging.
And then there's some timing differences because of the large inventories and medical device supply pipelines, but we do see it as an encouraging sign. And hopefully as the pandemic the pandemic subsides, there'll be less demand on hospital beds for COVID-nineteen. And people will be able to get back to some of these elective and semi elective procedures.
Great. I'll let somebody else ask some questions.
Speakers, I'm showing no further questions in the queue at this time. Correction, Jeff Bernstein has re queueed to ask questions. Your line is now open.
Great. Thanks. So, I was curious about the small stock repurchase in the quarter. Is that kind of reactivated now or is it valuation dependent or any commentary on that?
So it's, it wasn't reactivated. We do have an active repurchase program, but we have a number of constraints, legal constraints and so forth, that limit what we can buyback and then there are just market limitations, practical limitations. But as Kurt said, we thought our we think our stock is a good value admittedly, we might be a little bit biased, but we looked at it as a good opportunity. It's difficult to return. As a practical matter, it's difficult to return huge amounts of cash or large amounts of cash.
Through stock repurchases just because of the trading volume and so forth. So we rely on our dividends to return larger amounts of cash to our shareholders, but we also look at the possibility of buybacks situationally. And that depends on circumstances, outlook and so forth. But we thought it was an excellent opportunity, a relatively modest amount, but but still, we think it was a good value for getting the stock repurchased.
That's great. As do we. And then I was curious, you mentioned new products that now transfer both data and power. Is there like a buck or boost function in those? Are you actually changing the power that gets transmitted?
Yes, that's a great question for folks who aren't familiar with those terms. So, Buck means reducing the voltage as well as transferring energy and boost means to increase it. And those products that we introduced are neither. They're 3.3to3.3 so they produce the same voltage, roughly the same voltage as the input. But we are looking at, at a, boost version.
We haven't announced anything yet, but we're looking at increasing the voltage on the output. So that would be a boost function from 3.3to5andto3.3.26. So those are for different markets. The 3.3 to 5 is for certain buses, legacy buses that use Fibril buses, 5 volts is the bus voltage and 3.3 is a typical microcontroller. So it would provide an interface there.
And then 6 volts would allow us to drive power control MOSFETs. And so we actually have demos of that on our YouTube channel where we boost the voltage to 6 volts. That's one of the videos that I referred to in the prepared remarks. And that allows us to do power control with isolated completely isolated from a microcontroller, which is a very large market for motor controls, for power factor controls. So we see both of those particularly a boost from 3.3 to 6 volts as important products.
So those are part of our development roadmap and hopefully we'll be able to provide some more results there in future calls.
Great. Thank you. And then lastly, any update you can give us on auto design work?
Yes. We continue to see that as a market. It's longer term than say our industrial and process control type products, our industrial products, but we're continuing to work on qualifying our products in the automotive market, particularly our current sensors for motor control and battery management systems. And particularly for hybrid electric vehicles and autonomous vehicles, we see that as an excellent long term market There's going to be a lot more sensors and electronics components in those cars and cars going forward. And we see ourselves having an excellent benefit proposition with small size, low power and excellent accuracy.
So hopefully you'll be hearing more about that and we'll be able to tell you more about that in the future.
Thanks, Jeff.
Thank you. And I'm showing no further questions in the queue at this time. Like to turn the call back to Daniel Baker for any closing remarks.
We were pleased to report a solid profit in a challenging quarter and 4 new products. We look forward to speaking with you again in January to discuss third quarter results. Stay safe, everyone, and thank you for participating in the call.
Ladies and gentlemen, thank you for your participation on today's conference. This does conclude your program and you may now disconnect.